Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray
{"title":"嵌合抗原受体 T 细胞疗法后急性淋巴细胞白血病前葡萄膜浸润症状缓解","authors":"Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray","doi":"10.1177/24741264241275247","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. <b>Methods:</b> A retrospective case review was evaluated. <b>Results:</b> A 69-year-old woman with a history of B<b>-</b>ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. <b>Conclusions:</b> CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241275247"},"PeriodicalIF":0.5000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562240/pdf/","citationCount":"0","resultStr":"{\"title\":\"Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.\",\"authors\":\"Jaskirat S Takhar, Ankur A Mehra, Shree K Kurup, Warren M Sobol, Rabail Aslam, Kwadwo A Oduro, Jose J Echegaray\",\"doi\":\"10.1177/24741264241275247\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. <b>Methods:</b> A retrospective case review was evaluated. <b>Results:</b> A 69-year-old woman with a history of B<b>-</b>ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. <b>Conclusions:</b> CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.</p>\",\"PeriodicalId\":17919,\"journal\":{\"name\":\"Journal of VitreoRetinal Diseases\",\"volume\":\" \",\"pages\":\"24741264241275247\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562240/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of VitreoRetinal Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/24741264241275247\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264241275247","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:介绍一例采用嵌合抗原受体 T 细胞(CAR T)疗法治疗的急性 B 细胞淋巴细胞白血病(B-ALL)眼部复发病例。研究方法对病例进行回顾性评估。结果一名 69 岁的女性患者曾患 B-ALL 病史,出现双侧眼睑下垂和 3+ 前房细胞,对局部强的松龙治疗有反应。6 个月后,她的双眼反复出现视力减退、虹膜新生血管和虹膜结节。细针穿刺活检证实了 B-ALL 的眼部浸润。单次输注 CAR T 疗法后,全身和眼部症状均得到缓解。临床过程因细胞因子释放综合征和神经毒性而变得复杂,但经过药物治疗后情况有所改善。单次输注 CAR T 治疗后,患者病情持续缓解了 7 个月。结论CAR T疗法可有效治疗全身性白血病和葡萄膜浸润,同时具有眼部副作用和视觉效果。CAR T疗法的全身副作用可通过药物控制。
Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.
Purpose: To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. Methods: A retrospective case review was evaluated. Results: A 69-year-old woman with a history of B-ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. Conclusions: CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically.